This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

Plaintiffs oppose immediate appeal in US Xyrem antitrust case

( November 12, 2024, 23:31 GMT | Official Statement) -- MLex Summary: Jazz Pharmaceuticals and Hikma should not be allowed to immediately appeal an order regarding the amendment of a class in a US antitrust case accusing them of delaying a generic bioequivalent entry of Xyrem, according to plaintiffs. They argued the petition seeks to argue that the class should not have been certified at all, thereby challenging the district court’s denial of their decertification motion, which is not appealable. See attached file. ...

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login

Attached Documents

Related Sections